Several hallmarks of cancer cells are their display of metabolic changes and enhanced proliferation. Highly proliferating cells utilize glutamine as a source of nitrogen, and therefore, one of the commonly seen metabolic changes is increased glutaminolysis, or glutamine catabolism. In addition, glutamine is an important anaplerotic source by which cells support the pools of TCA cycle intermediates in Myc-expressing cancer cells. Glutamine is converted to aspartate, which forms oxaloacetate, malate, and pyruvate. These conversions increase the NADPH/NADP ＋ ratio and maintain redox balance, which supports proliferation in K-ras-expressing cells. Therefore, glutamine is important for cancer cell proliferation and survival. On the other hand, glutamine stimulates the activation of the tumor suppressor p53, which induces apoptosis and tumor regression. The tumor suppressor SIRT4 inhibits glutamate dehydrogenase, which converts glutamic acid to α-ketoglutarate, an intermediate in the TCA cycle. Overall, the expression levels of oncogenes and tumor suppressors are critical to determine whether glutamine supports or suppresses proliferation and survival of cancer cells. (J Cancer Prev 2013;18:221-226) 
INTRODUCTION
The global cancer incidence has been steadily increasing, along with its correlated morbidity and mortality. Therefore, there has been rising interest in cancer prevention in order to decrease or delay the initial carcinogenesis and development of premalignant cells. 1 One focus is on chemoprevention, which involves the use of natural, synthetic, or biological agents. 2, 3 Nutrients are also recognized as chemopreventive factors that significantly influence cancer development and prevention. The metabolism of nutrients such as glucose and glutamine, and the activity of plant-derived phytochemicals are associated with cancer suppression or prevention. [4] [5] [6] Glutamine plays several important roles in the cell. It serves as a constituent of protein, carbon source for energy production, and a precursor of antioxidant glutathione (GSH). Glutamine prevents inflammation by improving immune function 7 and is involved in signal transduction. 8 Although glutamine is traditionally considered to be a non-essential amino acid, it is conditionally essential during catabolic stress such as severe injury, trauma, and sepsis. 9 Most importantly, glutamine metabolism supports cell proliferation. Tumor cells display changes in metabolism induced by oncogenes, which also increase proliferation. 10 As a result of the energy demands in tumor cells, glutaminolysis, or glutamine catabolism, is heightened, as is aerobic glycolysis. 11 Specifically, glutamine supports the viability and proliferation of cancer cells by providing pools of TCA cycle intermediates and by the biosynthesis of proteins, lipids, and nucleotides. 12 In addition, glutaminolysis is required to suppress oxidative stress in cancer cells because glutamine participates in GSH synthesis. Glutamine also contributes to restoring GSH to its reduced form by increasing the production of NADPH through malic enzyme regulation. 13 In this review, One way p53 may mediate tumor suppression is through its induction of the expression of glutaminase 2 (GLS2). GLS is an enzyme that converts glutamate from glutamine, which is how GLS regulates GSH biosynthesis 19 and mitochondrial oxidative phosphorylation. There are two phosphate-activated GLS isoforms: GLS1 and GLS2. 20, 21 GLS1 is involved in cell proliferation, whereas GLS2 is associated with the cell resting or quiescent state. 21 GLS2 is induced in response to ROS in a p53-dependent manner, and overexpression of GLS2 results in a reduction of tumor cell growth. GLS2 levels were significantly reduced in liver tumors, and these results provide evidence that glutamine metabolism may contribute to the tumor suppressive role of p53.
Other experiments also show a relationship between p53
and glutamine in regards to tumor suppression. Oral glutamine supplementation increases phosphorylation of p53
and apoptosis in DMBA-induced mammary tumors. 5, 22 In this experiment, the levels of phosphorylated p53 in tumors of rats given glutamine supplementation were higher than those without glutamine supplementation. In addition, the expression of p21 . 25 In this experiment, B55α, one of the regulatory subunit of PP2A, was specifically induced during glutamine starvation in a ROS-dependent manner.
Additionally, B55α activates p53 through direct binding and dephosphorylation of EDD, an inhibitor of p53.
Glutamine is converted to glutamic acid, which is composed of GSH, 26 and during glutamine deprivation, GSH is reduced and ROS levels are increased in the cells. Increased ROS levels induce the expression of B55α and subsequently, the activation of p53. In other words, p53 is activated upon glutamine deprivation. Since there is controversy surrounding p53 activation and glutamine status (supplementation or deprivation), carefully designed studies should be performed to explore these complex relationships during different cell states.
Myc
Myc is a transcription factor that becomes deregulated in tumors. Myc is a proto-oncogene that promotes cell growth and regulates cell proliferation, 27, 28 and it is highly involved in glycolytic metabolism. 29 
SIRT4
Sirtuins are NAD ＋ -dependent deacetylases, targeting a wide variety of proteins in the nucleus, cytosol, and mitochondria. 35 Since sirtuins respond to cellular stress and DNA damage, they have been extensively studied as therapeutic targets for human diseases, such as cancer.
36,37
The sirtuin (SIRT) family consists of seven members (SIRT1-7), and each of the members differs in its activity and function. SIRT4 and SIRT6 catalyze ADP-ribosylations, whereas SIRT1, SIRT2, SIRT3, SIRT5, and SIRT7 catalyze deacetylation reactions. 38 Importantly, it has been reported that SIRT4 expression is reduced in cancer cells, and overexpression of SIRT4 inhibits cell proliferation and tumor development. 35, 39, 40 Previous studies have shown that SIRT4 inhibits glutamine dehydrogenase (GDH), 41 and it is well established that glutamine is an important source for TCA anaplerosis in proliferating cells. 42 Glutamate is produced from glutamine by glutaminase (GLS), and then glutamate is convertted to α-ketoglutarate by GDH. The α-ketoglutarate produced participates in the TCA cycle as an intermediate.
Jeong et al. demonstrated that SIRT4 inhibits glutamine
uptake and anaplerosis of cells with DNA damage, resulting in cell cycle arrest. 43 These findings suggest that SIRT4-mediated inhibition of glutamine anaplerosis may function as a tumor suppressor mechanism.
Another way in which the relationship between SIRT4
and glutamine may uncover information about potential cancer therapy targets was reported by Csibi et al. In this study, the activation of mammalian target of rapamycin complex 1 (mTORC1) was associated with increased glutamine metabolism. 44 Specifically, mTORC1 increased glutamine anaplerosis by activating GDH. Furthermore, mTORC1 mechanically inhibited SIRT4. This transcriptional repression of SIRT4 is essential for glutamine metabolism, and targeting glutamine metabolism in cancers with more active mTORC1 pathways may be useful for cancer therapy. Glutamine stimulates the activation of tumor suppressor p53, which induces apoptosis and tumor regression through the expression of p21. Also, p53 induces the expression of GLS2, which is associated with reductions in tumor growth (left panel). Glutamine is an important anaplerotic source that support pools of TCA cycle intermediates in Myc-expressing cancer cells. Glutamine is converted to aspartate, which forms oxaloacetate, malate, and pyruvate. These conversions increase the NADPH/NADP ＋ ratio and maintain redox balance, supporting proliferation in K-ras-expressing cells. The tumor suppressor SIRT4 inhibits GDH, which converts glutamic acid to the TCA cycle intermediate, α-ketoglutarate. mTORC1 mechanically inhibits SIRT4 and activates GDH (right panel). Overall, the expression levels of oncogenes and tumor suppressors are critical to determine whether glutamine supports or suppresses the proliferation and survival of cancer cells. GLS, glutaminase; GDH, glutamine dehydrogenase; SIRT4, Sirtuin4; mTORC1, mammalian target of rapamycin complex 1. With better understanding of glutamine metabolism in cancer and highly proliferating cells, we expect the use of glutamine for chemoprevention and cancer therapy to be a viable option in the future.
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